14 aug: Nye fastforrentede obligationer - Nykredit Realkredit A/S
14 aug: Coloplast leverer 8% organisk vækst og solide resultater på tværs..
14-08-2019 12:02:02

Coloplast Announcement no. 07/2019 - 9M Interim Financial Report, 2018/19

Interim financial report, 9M 2018/19

(01 October 2018 - 30 June 2019)                   

Solid underlying performance continues in Q3

  • Coloplast delivered 8% organic growth in the third quarter. Year to date organic growth was also 8% while reported revenue in DKK was up by 9% to DKK 13,321m.
  • Organic growth rates by business area year to date: Ostomy Care 7%, Continence Care 8%, Interventional Urology 10% and Wound & Skin Care 9%.  
  • Continued strong momentum in Europe with 6% organic growth in the first three quarters, driven by all business areas.
  • Positive performance within Chronic Care in the US in Q3 with double-digit growth, driven by the hydrophilic upgrade in catheters and market share gains in Ostomy Care.
  • The Wound Care business delivered 8% organic growth year to date, driven by the Biatain® Silicone portfolio in Europe and in particular France and the UK.
  • The Interventional Urology business delivered 10% organic growth year to date, driven by sales and marketing investments in the US.
  • Improved momentum in Emerging Markets in Q3 driven by increased tender activity in Russia and solid momentum in China.
  • The French reimbursement reform in Ostomy Care, Continence Care and Wound Care has been announced. For Coloplast, the price reform represents an average reduction in prices in France for Ostomy Care and Continence Care of ~9% and Wound Care of ~2%.
  • The incremental investments into innovation and sales and marketing initiatives of up to 2% of revenue that were initiated in Q1 are making satisfactory progress.
  • EBIT amounted to DKK 4,077m for the first nine months, a 11% increase in DKK, corresponding to an EBIT margin of 31% against 30% last year. The last volume factory in Denmark, Thisted, has now been closed and restructuring costs of DKK 43m were included in the first nine months in connection with the reduction of production staff in Denmark.
  • ROIC after tax before special items was 45% in the first nine months against 42% in the same period last year.
  • Coloplast is conducting an unconditional strategic review of the Interventional Urology division. The review is expected to be concluded by the end of 2019.

Financial guidance for 2018/19

  • We continue to expect organic revenue growth of ~8% at constant exchange rates and a reported growth in DKK of ~9%.
  • We continue to expect an EBIT margin of 30-31% at constant exchange rates and ~31% in DKK. The EBIT margin guidance reflects additional incremental investments of up to 2% of revenue for innovation and sales and marketing purposes.
  • Capital expenditure is expected to be DKK ~700m.
  • The effective tax rate is expected to be about ~23%.



For more information, please contact:

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel. +45 4911 1111

Ellen Bjurgert

Vice President

Investor Relations

Tel. +45 4911 1800 / 4911 3376

E-mail dkebj@coloplast.com

Rasmus Sørensen

Senior Manager

Investor Relations

Tel. +45 4911 1800 / 4911 1786

E-mail dkraso@coloplast.com

Press and the media

Dennis Kaysen

Director

Corporate Communications

Tel. +45 4911 2608

E-mail dkdk@coloplast.com

Lina Danstrup

Senior Media Relations Manager

Corporate Communications

Tel. +45 4911 2607

E-mail dklina@coloplast.com

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Business reg. (CVR) no. 69749917

Website

www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2019-08.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment

Primary Logo

Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
23 aug
GEN
For Genmab investorer bliver september måned en hot affære - der kommer i hvert fald en stribe nyhed..
41
19 aug
OMXC25
Endnu en dansk patriark er død. Ære være hans minde.
29
25 aug
VELO
Det er interessant at kigge på Veloxis vækst og nuværende position i markedet for at regne frem til ..
26
21 aug
I:NDX
Trump er en forretningsmand, der bevæger sig med en forretningsmands hastighed. Han er fløjtende lig..
21
22 aug
 
Jeg synes hun gjorde det fremragende i sagen om Grønland og Trump.   Det vigtigste i en sådan situat..
20
20 aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
20 aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
18
19 aug
OMXC25
En fantastisk dygtig og sympatisk erhvervsmand.  Og en ægte patriot som også betalte sin skat med gl..
18
24 aug
GOMX
Har aktien:   GOMSPACE: TECKNAR AVTAL MED ESA VÄRT 1,4 MLN EUR 19:26STOCKHOLM (Nyhetsbyrån Direkt) R..
15
23 aug
VELO
Netop i denne måned har jeg været på EuroInvestor i 1 år og manglede, for at sige det mildt, baggrun..
15

Vestas' største kinesiske konkurrent oplever dyk i overskuddet

23-08-2019 15:14:38
Den kinesiske vindmølleproducent Goldwind, som er verdens næststørste af sin slags efter Vestas, måtte i første halvår se sit overskud skrumpe med 22,6 pct. til 1,18 mia. yuan.Omsætningen for perioden er opgjort til 15,73 mia. yuan, fremgår det af Bloomberg News.Goldwind havde i 2018 en markedsandel globalt på 14,7 pct. - og var dermed nummer to efter Vestas med en andel på 22,2 pct.Nummer tre var..

Kina gengælder amerikansk told: Aktiefutures falder

Relaterede nyheder
23-08-2019 14:27:22
Kina vil indføre told på 5-10 pct. på amerikanske varer for yderligere 75 mia. dollar som en gengældelse af amerikanernes told på varer, som importeres fra Kina.Tolden indføres i to etaper henholdsvis 1. september og 1. december.Det skriver Bloomberg News.Ifølge det kinesiske medie Xinhua varsler Kina også en told på 25 pct. på amerikanske biler fra 15. december, og sojaimporten fra USA pålægges e..

Sydbank sænker Ambu-anbefaling - flere finanshuse retter kursmål efter nedjustering

23-08-2019 11:27:06
Sydbank ser en aktie i Ambu som "mindre attraktiv" end tidligere, efter medicoselskabet senest i denne uge skar i forventningerne til resultaterne for hele 2018/19.Derfor sættes anbefalingen ned til "hold" fra "køb", skriver Søren Løntoft Hansen, senioraktieanalytiker i Sydbank.- I kølvandet på strategiopdateringen i juni og gårsdagens melding om investeringerne i det direkte salg i USA har vi sæn..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. august 2019 03:44:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190819.1 - EUROWEB3 - 2019-08-26 03:44:43 - 2019-08-26 03:44:43 - 1 - Website: OKAY